Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

iBio Inc., GE Healthcare form global alliance

By Drug Discovery Trends Editor | July 26, 2012

iBio Inc. and
GE Healthcare announced a new global alliance to commercialize plant-based
technologies for the manufacture of biopharmaceuticals and vaccines. The
alliance builds on the existing development and marketing agreement between the
two companies announced in 2010 and combines iBio’s plant-based vaccine
manufacturing platform, iBioLaunch, with GE Healthcare’s capabilities in
start-to-finish technologies for biopharmaceutical manufacturing. iBio’s
R&D collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB)
will continue to play a key role in advancing the iBioLaunch platform. Financial
terms were not disclosed.

The iBioLaunch platform is a proprietary gene expression
technology that induces plants to rapidly produce high levels of proteins such as
vaccines, in a process which can be easily and reliably scaled-up in low cost,
controlled-growth facilities. GE Healthcare develops and produces
start-to-finish technologies and tools used for the manufacture of
biopharmaceuticals, vaccines, and other protein-based therapeutics. GE
Healthcare’s global team of bioengineers and bioprocessing scientists are
working with researchers from iBio and CMB to develop a single, flexible
facility which could significantly reduce the capital and operating costs of
biotherapeutic and vaccine manufacture compared with traditional animal cell
and microbial based methods. The iBioLaunch platform also has the potential to
manufacture proteins which cannot be commercially produced in any other system.

Worldwide
demand for biopharmaceuticals and vaccines is increasing dramatically, driven
by ageing populations and the global effort to reduce the incidence of vaccine
preventable diseases. In work funded by the Bill & Melinda Gates
Foundation, iBio’s plant-based technology has been used to produce an avian
influenza vaccine candidate that recently completed a successful Phase I
clinical trial. The iBioLaunch platform was also used to produce a candidate
vaccine against H1N1 influenza, for which a human Phase I trial was
successfully completed in March, 2012.  The alliance between the two
companies aligns with GE’s healthymagination initiative, which focuses on
reducing cost, increasing access and improving quality in health care.

GE Healthcare


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE